Quince Therapeutics

Quince Therapeutics is a late-stage biotechnology company aiming to leverage the patient’s own biology for the treatment of rare diseases. The company's Phase 3 lead asset, EryDex, utilizes the proprietary Autologous Intracellular Drug Encapsulation (AIDE) technology platform, which encapsulates a drug into the patient’s own red blood cells. This unique approach offers potential benefits such as improved tolerability, enhanced tissue distribution, reduced immunogenicity, and prolonged circulating half-life. EryDex, containing dexamethasone sodium phosphate (DSP) encapsulated in autologous red blood cells, targets the treatment of the rare pediatric neurodegenerative disease, Ataxia-Telangiectasia (A-T). The company is currently enrolling patients in the pivotal Phase 3 NEAT study, with an expected assessment in the fourth quarter of 2025. If the results are positive, a New Drug Application (NDA) submission to the FDA and a Marketing Authorization (MAA) submission to the European Medicines Agency (EMA) are anticipated in 2026. Quince was granted Fast Track designation by the FDA for the EryDex System, acknowledging its potential to address A-T's high unmet medical need. Quince Therapeutics was founded in 2012 and operates in the biotechnology, health care, and pharmaceutical industries. Their last known investment was a Post-IPO Equity investment at 13 December 2019.